One shot to ease knee pain? new gel injection put to the test
NCT ID NCT07746843
First seen Aug 05, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This trial tests whether a single injection of a new gel, called 2107, can relieve pain and improve function in people with mild-to-moderate knee osteoarthritis. About 286 adults aged 40–80 will receive either 2107 or an existing hyaluronic acid injection (DUROLANE) directly into the knee. Researchers will track pain, stiffness, and physical function over 26 weeks to see if 2107 works as well as the current option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 2107 Injection (a hyaluronic acid-based gel injected into the knee joint)
- What this could lead to
- If it works, this could offer a new, single-injection option to reduce knee pain and improve mobility in people with mild-to-moderate osteoarthritis.
- What could go wrong
- The trial is early and compares against an existing treatment, so it may not prove better or even as good. As with any joint injection, there is a risk of temporary pain, swelling, or infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD KNEE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenterMed Krakow Sp. z o.o.
Krakow, Lesser Poland Voivodeship, 31-530, Poland
-
Corporació Sanitària Parc Taulí
Sabadell, Barcelona, 08208, Spain
-
NHS Greater Glasgow and Clyde
Glasgow, Scotland, G51 4TF, United Kingdom